World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
59
Citations
15079
World Ranking
3405
National Ranking
294

Sarah Fidler publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Sarah Fidler sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 433 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Sarah Fidler D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Sarah Fidler sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 59 D-Index — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Sarah Fidler is affiliated with Imperial College London in the United Kingdom. Their research primarily focuses on medicine, with significant contributions to immunology and microbiology. Their work spans several subfields, including infectious diseases, virology, epidemiology, general health professions, and immunology.

The scientist's main topics of research encompass HIV/AIDS research and interventions, HIV research and treatment, adolescent sexual and reproductive health, HIV related to drug use and sexual risk, HIV/AIDS drug development and treatment, HIV-related health complications and treatments, and SARS-CoV-2 and COVID-19 research.

Frequent co-authors collaborating with Sarah Fidler include:

  • Helen Ayles
  • Richard Hayes
  • Sian Floyd
  • Peter Bock
  • Kwame Shanaube

Sarah Fidler has published extensively in various reputable scientific venues. These include:

  • Journal of the International AIDS Society
  • SSRN Electronic Journal
  • bioRxiv (Cold Spring Harbor Laboratory)
  • The Lancet HIV
  • PLOS Global Public Health

Recent publications by Sarah Fidler encompass a range of topics related to HIV and immunology:

  • Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021, 2021, Nature Medicine
  • Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial, 2021, The Lancet HIV
  • Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans, 2021, Nature Immunology
  • Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial, 2022, EClinicalMedicine
  • What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?, 2020, Journal of the International AIDS Society

Best Publications

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Adaptation of HIV-1 to human leukocyte antigen class I

    Y. Kawashima;K. Pfafferott;J. Frater;P. Matthews

  • Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis.

    Sung-Hee Kim;Sarah M. Gerver;Sarah Fidler;Helen Ward

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • International AIDS Society global scientific strategy: towards an HIV cure 2016

    Steven G Deeks;Sharon R Lewin;Anna Laura Ross;Jintanat Ananworanich

  • Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.

    Steven G. Deeks;Nancie Archin;Paula Cannon;Simon Collins

  • Effect of universal testing and treatment on HIV incidence - HPTN 071 (popart)

    Richard J Hayes;Deborah Donnell;Sian Floyd;Nomtha Mandla

  • HIV-1 DNA predicts disease progression and post-treatment virological control

    James P Williams;Jacob Hurst;Jacob Hurst;Wolfgang Stöhr;Nicola Robinson;Nicola Robinson

  • HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.

    Richard Derek Hayes;Helen Ayles;Helen Ayles;Nulda Beyers;Kalpana Sabapathy

  • Short-course antiretroviral therapy in primary HIV infection.

    S Fidler;K Porter;F Ewings

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis.

    Kalpana Sabapathy;Rafael Van den Bergh;Sarah Fidler;Richard Derek Hayes

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

    J Frater;K J Ewer;A Ogbe;M Pace

  • Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

    Unknown

  • Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans.

    Kathleen B. Yates;Kathleen B. Yates;Pierre Tonnerre;Pierre Tonnerre;Genevieve E. Martin;Genevieve E. Martin;Ulrike Gerdemann

  • Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men.

    Julie Fox;Peter J White;Peter J White;Neil Macdonald;Jonathan Weber

  • Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

    Jacob Hurst;Matthias Hoffmann;Matthew Pace;Matthew Pace;James P. Williams

  • Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.

    Matthias Hoffmann;Matthias Hoffmann;Nikos Pantazis;Genevieve E. Martin;Stephen Hickling

  • Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

    Unknown

  • What do the Universal Test and Treat trials tell us about the path to HIV epidemic control

    Diane Havlir;Shahin Lockman;Shahin Lockman;Helen Ayles;Joseph Larmarange

  • Sexual transmission of HIV-1.

    Julie Fox;Sarah Fidler

  • Clinical and public health implications of acute and early HIV detection and treatment: a scoping review

    Sarah E. Rutstein;Jintanat Ananworanich;Sarah Fidler;Cheryl Johnson

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

    Duncan Churchill;Laura Waters;Nadia Ahmed;Brian Angus

Frequent Co-Authors

John Frater
John Frater University of Oxford
Richard J. Hayes
Richard J. Hayes London School of Hygiene & Tropical Medicine
Julie Fox
Julie Fox Guy's and St Thomas' NHS Foundation Trust
Kholoud Porter
Kholoud Porter University College London
Rodney E. Phillips
Rodney E. Phillips University of Oxford
Alan Winston
Alan Winston Imperial College London
Jonathan Weber
Jonathan Weber Imperial College London
Paul Klenerman
Paul Klenerman University of Oxford
Martin Fisher
Martin Fisher University of Sussex
Nulda Beyers
Nulda Beyers Stellenbosch University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare fields can open diverse career opportunities. Nursing practitioners with a focus on psychiatric and mental health are in high demand. To support this, many students seek the best pmhnp programs online, which offer strong clinical placement support to ensure practical experience alongside flexible learning.

Financing advanced degrees is a key consideration. Prospective students often look into the affordable pmhnp programs to pursue their education without excessive debt. These programs balance cost-effectiveness with quality instruction, making them attractive options.

Career advancement and salary potential are also critical factors. Understanding how much do dnp nurses make across different states can help guide decisions about where to study and work. Salaries vary widely, reflecting regional demand and specialization.

Transitioning between nursing specialties is common for career growth. For example, nurses often explore pathways such as fnp to acnp transitions, allowing them to expand their scope and expertise in acute care settings.

Overall, integrating immunology studies with targeted nursing programs and informed career planning can provide a strong foundation for long-term success in healthcare.

Best Scientists Citing Sarah Fidler

Trending Scientists

Recently Published Articles